The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
Yung-Jue Bang
No relevant relationships to disclose
Yoon-Koo Kang
No relevant relationships to disclose
Maria Alsina
No relevant relationships to disclose
Zev A. Wainberg
No relevant relationships to disclose
Ian Chau
No relevant relationships to disclose
Jin Zhu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Wai Y. Chan
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Premal H. Patel
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Raymond D. Meng
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jaffer A. Ajani
No relevant relationships to disclose